The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

Mon, 08th Jan 2024 09:11

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

N4 is a Derbyshire, England-based pharmaceutical company. It is focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics.

Through its research programme with the University of Brunel, N4 Pharma completed a series of in vitro experiments, where Nuvec was mixed with AAV8 and used to transduce human-like liver cells.

When the viral vector was complexed with Nuvec, transduction efficacy increased 2.5-fold, compared to the AAV8 vector when used on a standalone basis.

These most recent experiments build on earlier work, which showed that Nuvec increased the transduction efficacy of a standard Adenovirus vector.

"Our work shows that Nuvec has the potential to reduce the amount of AV and AAV needed and thus decrease both the cost of goods and immunogenicity associated with using these viral vectors. We believe this will be a major focus of the pharma/biotech industry as these viral vector delivery systems are further investigated," said Chief Executive Officer Nigel Theobald.

"This work is running in parallel to our ongoing oral and dual loading work as well as the Nanogenics' Glaucoma product, an update on which will follow soon."

Shares in the firm were up 2.9% at 1.34 pence each in London on Monday morning.

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
18 Jun 2018 11:54

N4 Pharma Says Team Making Progress In Nuvec Manufacturing Process

LONDON (Alliance News) - Drug reformulator N4 Pharma PLC said Monday work to develop a manufacturing process for Nuvec has begun "well" with the team making progress.Nuvec is a to

Read more
9 May 2018 14:13

N4 Pharma Files Patent For Drug To Treat Premature Ejaculation

LONDON (Alliance News) - Pharmaceutical company N4 Pharma PLC announced on Wednesday it has filed a patent application for a treatment for premature ejaculation.N4 Pharm's drug is an of

Read more
25 Apr 2018 11:54

N4 Pharma Outlook Optimistic But Loss Widens After Reverse Takeover

LONDON (Alliance News) - N4 Pharma PLC on Wednesday said it remains optimistic for future as progresses its drug and vaccine development, but the company's loss widened in 2017 following its a

Read more
18 Apr 2018 12:15

N4 Pharma Starts Clinical Trial Of Reformulated Sildenafil

LONDON (Alliance News) - N4 Pharma PLC said Wednesday that it has commenced proof of concept clinical trial for erectile dysfunction treatment drug sildenafil, following the completion of the of a

Read more
9 Mar 2018 10:43

N4 Pharma Raises Nets GBP159,700 From Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Friday it issued 1.9 million shares due to exercise of warrants, raising GBP159,700 for the pharmaceutical warrants

Read more
8 Mar 2018 13:34

N4 Pharma Unveils Two-Pronged Strategy For Nuvec Development

LONDON (Alliance News) - N4 Pharma PLC announced Thursday a two-fold development strategy for its Nuvec technology, as well as a new head of development for Nuvec.Nuvec

Read more
7 Mar 2018 12:41

N4 Pharma Raises Further GBP30,451 After Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Wednesday it issued 358,245 shares due to exercise of warrants, raising GBP30,451 for the pharmaceutical warrants at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.